文献速递消化道肿瘤与早癌消化内镜

基于遗传与环境风险因素的结直肠癌风险分层筛查:基于真实世界数据的成本效果分析

Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-03-09

研究利用大型社区队列的真实世界数据预测结直肠癌及竞争性死因风险,将人群分层并微模拟优化各组结肠镜起始年龄、终止年龄和间隔;风险分层筛查个体方案差异大,但人群水平净质量调整生命年增益仅提高0.7%或平均成本仅降低1.2%。

要点

  • 风险分层筛查可使个体方案从低危60岁一次结肠镜到高危40至85岁每5年一次。
  • 与统一筛查相比,人群净质量调整生命年增益仅提高0.7%或平均成本仅降低1.2%。
  • 若假设提高参与率或降低基因检测成本,风险分层筛查的获益可改善。

核心结论

  • 考虑竞争性死因风险的个人化结直肠癌筛查可产生高度定制的个体筛查方案,但人群平均质量调整生命年增益和成本效果改善较小。

研究设计与样本

  • 基于大型社区队列的真实世界数据预测结直肠癌和竞争性死因风险并分层,采用微模拟模型优化各组结肠镜筛查。
  • 优化参数包括起始年龄40至60岁、终止年龄70至85岁和筛查间隔5至15年,并与统一结肠镜筛查(45至75岁、每10年一次)比较。

主要发现

  • 风险分层筛查建议从低危个体60岁一次结肠镜到高危个体40至85岁每5年一次结肠镜,差异显著。
  • 人群水平上,风险分层筛查在成本相等时净质量调整生命年增益仅提高0.7%,或在质量调整生命年增益相等时平均成本仅降低1.2%。
  • 当假设风险分层筛查提高参与率或每次基因检测成本更低时,其获益改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Previous studies on the cost-effectiveness of personalized colorectal cancer (CRC) screening were based on hypothetical performance of CRC risk prediction and did not consider the association with competing causes of death. In this study, we estimated the cost-effectiveness of risk-stratified screening using real-world data for CRC risk and competing causes of death. METHODS: Risk predictions for CRC and competing causes of death from a large community-based cohort were used to stratify individuals into risk groups. A microsimulation model was used to optimize colonoscopy screening for each risk group by varying the start age (40-60 years), end age (70-85 years), and screening interval (5-15 years). The outcomes included personalized screening ages and intervals and cost-effectiveness compared with uniform colonoscopy screening (ages 45-75, every 10 years). Key assumptions were varied in sensitivity analyses. RESULTS: Risk-stratified screening resulted in substantially different screening recommendations, ranging from a one-time colonoscopy at age 60 for low-risk individuals to a colonoscopy every 5 years from ages 40 to 85 for high-risk individuals. Nevertheless, on a population level, risk-stratified screening would increase net quality-adjusted life years gained (QALYG) by only 0.7% at equal costs to uniform screening or reduce average costs by 1.2% for equal QALYG. The benefit of risk-stratified screening improved when it was assumed to increase participation or costs less per genetic test. CONCLUSIONS: Personalized screening for CRC, accounting for competing causes of death risk, could result in highly tailored individual screening programs. However, average improvements across the population in QALYG and cost-effectiveness compared with uniform screening are small.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. van den Puttelaar R, Meester RGS, Peterse EFP, et al. Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data. Clin Gastroenterol Hepatol. 2023. PMID: 36906080. doi:10.1016/j.cgh.2023.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。